文献速递头颈与中枢神经肿瘤支持与姑息治疗

儿童药品研发中的丝裂原活化蛋白激酶通路抑制剂策略论坛:ACCELERATE与欧洲药品管理局合作、美国食品药品监督管理局参与

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
PubMed 文献 · Eur J Cancer · 2022-10-14

第九届儿科策略论坛聚焦MAPK通路抑制剂在儿童癌症中的开发。MAPK通路在多种儿童肿瘤中激活,但现有抑制剂疗效和缓解持续时间需改进。论坛强调需基于生物学深入理解快速开发联合方案,加速将MAPK抑制剂引入前线儿童研究,并确保长期随访。

要点

  • MAPK通路在多种儿童肿瘤中激活,是重要治疗靶点。
  • MAPK抑制剂在儿童癌症中显示活性,但缓解率和缓解持续时间需改进和更好记录。
  • 需基于生物学深入理解快速开发联合方案,避免矛盾性肿瘤生长和严重毒性。

核心结论

  • MAPK抑制剂在儿童癌症中显示活性,但缓解率和缓解持续时间需改进和更好记录。
  • 需基于对生物学的深入理解快速开发和评估联合方案,以优化缓解并避免矛盾性肿瘤生长和其他意外后果包括严重毒性。
  • 需系统协调的临床研究而非临床试验外使用,以全面评估这些单药和联合策略在一线和难治/复发 setting 中的风险与获益。
  • 加速将MAPK抑制剂引入前线儿童研究是优先事项,同时确保这些研究产生适合科学和监管目的的数据。
  • 鉴于MAPK抑制剂长期给药及该通路在正常发育中的重要参与,对接受MAPK抑制剂患者的长期随访至关重要。

研究设计与样本

  • 第九届儿科策略论坛,聚焦MAPK抑制剂,由ACCELERATE与欧洲药品管理局合作、美国食品药品监督管理局参与。

主要发现

  • MAPK通路信号通过多种级联和反馈环路,扰动MAPK通路可能对其他通路及正常发育产生实质影响。
  • MAPK通路抑制剂的开发迄今主要由成人适应症如恶性黑色素瘤驱动。
  • 这些抑制剂可能针对儿童低级别胶质瘤、高级别胶质瘤、朗格汉斯细胞组织细胞增生症、幼年型粒单核细胞白血病及其他几种儿童疾病中未满足的需求。
  • MAPK抑制剂在儿童癌症中已显示活性,但缓解率和缓解持续时间需改进和更好记录。
  • 需要研究具有更高中枢神经系统穿透性的更好抑制剂用于原发性脑肿瘤和有中枢神经系统转移倾向的癌症,以确定是否比当前所用药物更有效,并需确定MAPK抑制的最佳治疗持续时间。

临床怎么用

  • 需要系统协调的临床研究而非临床试验外使用,以全面评估MAPK抑制剂单药和联合策略在一线和难治/复发 setting 中的风险与获益。
  • 平台试验可解决多个类似产品和联合方案的考察。
  • 加速将MAPK抑制剂引入前线儿童研究是优先事项,并确保这些研究产生适合科学和监管目的的数据。
  • 与监管机构的早期讨论至关重要,特别是如果考虑外部对照,因为小患者人群中的随机对照试验可能具有挑战性。
  • 特定于所研究人群的功能性终点如视力、运动和神经心理功能很重要,应纳入儿童低级别胶质瘤的初始研究设计。

局限性

  • MAPK抑制剂在儿童癌症中已显示活性,但缓解率和缓解持续时间需改进和更好记录。
  • 需基于对生物学的深入理解快速开发和评估联合方案,以避免矛盾性肿瘤生长和其他意外后果包括严重毒性。
  • 需要研究具有更高中枢神经系统穿透性的更好抑制剂用于原发性脑肿瘤和有中枢神经系统转移倾向的癌症,以确定是否比当前所用药物更有效。
  • 需确定MAPK抑制的最佳治疗持续时间。
  • 小患者人群中的随机对照试验可能具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK pathway inhibitors are being developed in adults. However, MAPK signals through many cascades and feedback loops and perturbing the MAPK pathway may have substantial influence on other pathways as well as normal development. In view of these issues, the ninth Paediatric Strategy Forum focused on MAPK inhibitors. Development of MAPK pathway inhibitors to date has been predominantly driven by adult indications such as malignant melanoma. However, these inhibitors may also target unmet needs in paediatric low-grade gliomas, high-grade gliomas, Langerhans cell histiocytosis, juvenile myelomonocytic leukaemia and several other paediatric conditions. Although MAPK inhibitors have demonstrated activity in paediatric cancer, the response rates and duration of responses needs improvement and better documentation. The rapid development and evaluation of combination approaches, based on a deep understanding of biology, is required to optimise responses and to avoid paradoxical tumour growth and other unintended consequences including severe toxicity. Better inhibitors with higher central nervous systempenetration for primary brain tumours and cancers with a propensity for central nervous system metastases need to be studied to determine if they are more effective than agents currently being used, and the optimum duration of therapy with MAPK inhibition needs to be determined. Systematic and coordinated clinical investigations to inform future treatment strategies with MAPK inhibitors, rather than use outside of clinical trials, are needed to fully assess the risks and benefits of these single agents and combination strategies in both front-line and in the refractory/relapse settings. Platform trials could address the investigation of multiple similar products and combinations. Accelerating the introduction of MAPK inhibitors into front-line paediatric studies is a priority, as is ensuring that these studies generate data appropriate for scientific and regulatory purposes. Early discussions with regulators are crucial, particularly if external controls are considered as randomised control trials in small patient populations can be challenging. Functional end-points specific to the populations in which they are studied, such as visual acuity, motor and neuro psychological function are important, as these outcomes are often more reflective of benefit for lower grade tumours (such as paediatric low-grade glioma and plexiform neurofibroma) and should be included in initial study designs for paediatric low-grade glioma. Early prospective discussions and agreements with regulators are necessary. Long-term follow-up of patients receiving MAPK inhibitors is crucial in view of their prolonged administration and the important involvement of this pathway in normal development. Further rational development, with a detailed understanding of biology of this class of products, is crucial to ensure they provide optimal benefit while minimising toxicity to children and adolescents with cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pearson AD, Allen C, Fangusaro J, et al. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022. PMID: 36335782. doi:10.1016/j.ejca.2022.09.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。